 <h1>Kalydeco Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ivacaftor</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ivacaftor. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kalydeco.</p><h2>In Summary</h2><p><b>Common side effects of Kalydeco include:</b> dizziness.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ivacaftor: oral granule, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ivacaftor (the active ingredient contained in Kalydeco) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ivacaftor:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty with breathing or trouble breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dark urine</li>
<li>fever with or without chills</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>stomach pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ivacaftor may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>muscle aches, pain, or stiffness</li>
<li>pain in the joints</li>
<li>pimples</li>
<li>rash</li>
</ul><p>
<!-- end oral granule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivacaftor: oral granule for reconstitution, oral tablet</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Acne<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (22%), abdominal pain (16%), diarrhea (13%), nausea (12%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Maximum transaminase (ALT or AST) levels of greater than 8 times upper limit of normal (ULN), greater than 5 times ULN, and greater than 3 times ULN were reported in 2%, 3%, and 6% of patients treated with ivacaftor (the active ingredient contained in Kalydeco)  respectively.</p>
<p></p>
<p>In patients aged 12 months to less than 24 months (N=19), the incidence transaminase elevations (ALT or AST) greater than 3, greater than 5, and greater than 8 times the upper limit of normal (x ULN) was 27.8% (5/18), 11.1% (2/18) and 11.1% (2/18), respectively.  In patients aged 6 months to less than 12 months (N=11) one patient (9.1%) had elevated ALT of greater than 3 to less than or equal to 5 x ULN.  No patients had elevations in total bilirubin, or discontinued ivacaftor treatment due to transaminase elevations.<sup>[Ref]</sup></p><p>Very Common (10% or more): Transaminase elevations (up to 27.8%) </p>
<p><b>Common</b> (1% to 10%): Increased aspartate aminotransferase, increased hepatic enzymes, transaminase elevations<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Increased blood glucose<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, musculoskeletal chest pain, myalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (24%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, sinus headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (14.7%)</p>
<p><b>Common</b> (1% to 10%): Bacteria in sputum, ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, ear congestion<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (22%), nasal congestion (20%), nasopharyngitis (15%), cystic fibrosis lung (38.5%), cough (36.7%), productive cough (12.8%), rales (10%)</p>
<p><b>Common</b> (1% to 10%): Rhinitis, pharyngeal erythema, pleuritic pain, sinus congestion, wheezing<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Breast mass</p>
<p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Non-congenital lens opacities/cataracts (in pediatric patients up to 12 years of age)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Symdeko and Orkambi?</li>
<li>What is the difference between Symdeko and Kalydeco?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Kalydeco (ivacaftor)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: CFTR potentiators</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kalydeco &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ivacaftor: oral granule for reconstitution, oral tablet</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 13%)</p><p><b>Common</b> (1% to 10%): Acne<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Oropharyngeal pain (22%), abdominal pain (16%), diarrhea (13%), nausea (12%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Maximum transaminase (ALT or AST) levels of greater than 8 times upper limit of normal (ULN), greater than 5 times ULN, and greater than 3 times ULN were reported in 2%, 3%, and 6% of patients treated with ivacaftor (the active ingredient contained in Kalydeco)  respectively.</p><p></p><p>In patients aged 12 months to less than 24 months (N=19), the incidence transaminase elevations (ALT or AST) greater than 3, greater than 5, and greater than 8 times the upper limit of normal (x ULN) was 27.8% (5/18), 11.1% (2/18) and 11.1% (2/18), respectively.  In patients aged 6 months to less than 12 months (N=11) one patient (9.1%) had elevated ALT of greater than 3 to less than or equal to 5 x ULN.  No patients had elevations in total bilirubin, or discontinued ivacaftor treatment due to transaminase elevations.<sup>[Ref]</sup></p><p>Very Common (10% or more): Transaminase elevations (up to 27.8%) </p><p><b>Common</b> (1% to 10%): Increased aspartate aminotransferase, increased hepatic enzymes, transaminase elevations<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Increased blood glucose<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, musculoskeletal chest pain, myalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (24%)</p><p><b>Common</b> (1% to 10%): Dizziness, sinus headache<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (14.7%)</p><p><b>Common</b> (1% to 10%): Bacteria in sputum, ear discomfort, ear pain, tinnitus, tympanic membrane hyperemia, ear congestion<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (22%), nasal congestion (20%), nasopharyngitis (15%), cystic fibrosis lung (38.5%), cough (36.7%), productive cough (12.8%), rales (10%)</p><p><b>Common</b> (1% to 10%): Rhinitis, pharyngeal erythema, pleuritic pain, sinus congestion, wheezing<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Breast mass</p><p><b>Uncommon</b> (0.1% to 1%): Breast inflammation, gynecomastia, nipple disorder, nipple pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Non-congenital lens opacities/cataracts (in pediatric patients up to 12 years of age)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Symdeko and Orkambi?</li>
<li>What is the difference between Symdeko and Kalydeco?</li>
</ul><h2>More about Kalydeco (ivacaftor)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: CFTR potentiators</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kalydeco &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>